PEGA vs SLAB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
PEGA exhibits strong fundamental health with a Piotroski F-Score of 8/9 and an exceptional ROE of 57.32%, indicating efficient internal operations and a clean balance sheet. While the current price of $43.80 sits well below the growth-based intrinsic value of $62.83 and analyst targets, it is significantly above the defensive Graham Number of $14.88. The primary conflict lies between stellar profitability/health and anemic revenue growth (2.70%), coupled with bearish insider activity and a negative technical trend. The overall outlook is tempered by significant legal risks associated with Appian Corp.
SLAB exhibits a severe disconnect between its market price and fundamental operational health, highlighted by a weak Piotroski F-Score of 2/9. While the company maintains an exceptionally clean balance sheet with minimal debt and high liquidity, it remains unprofitable with negative net and operating margins. The stock has experienced a massive 135% price surge over the last year, pushing it to its 52-week high despite a high PEG ratio of 3.12 and bearish insider selling. The current valuation appears speculative, relying on EPS recovery rather than established financial stability.
Compare Another Pair
Related Comparisons
PEGA vs SLAB: Head-to-Head Comparison
This page compares Pegasystems Inc. (PEGA) and Silicon Laboratories Inc. (SLAB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.